Publication:
Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

dc.contributor.coauthorAfsar, Barıs
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBalık, Emre
dc.contributor.kuauthorBuğra, Dursun
dc.contributor.kuauthorDağel, Tuncay
dc.contributor.kuauthorDilege, Şükrü
dc.contributor.kuauthorErus, Suat
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorMandel, Nil Molinas
dc.contributor.kuauthorMısırlıoğlu, Selim
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.kuauthorTanju, Serhan
dc.contributor.kuauthorTaşkıran, Çağatay
dc.contributor.kuauthorVatansever, Doğan
dc.contributor.kuauthorYaltı, Mehmet Tunç
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:10:34Z
dc.date.issued2018
dc.description.abstractPurpose: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) or hyperthermic intrapleural chemotherapy (HIC) has been established as the new treatment modality for selected patients with peritoneal and pleural malignancies. The purpose of the study was to compare the development of acute kidney injury (AKI) in patients who received intravenous cisplatin alone, HIPEC and underwent surgery. Methods: This retrospective study included 104 patients who underwent different therapeutic procedures including systemic cisplatin, surgery and HIPEC or HIC using cisplatin for the treatment of peritoneal carcinomatosis from a variety of primary tumors at Koc University Hospital and American Hospital between January 2015 to December 2017. Results: AKI developed in 18 (17.3%) patients. Baseline creatinine was significantly increased in 3 groups after therapies. The development of AKI was highest in patients treated with HIPEC compared to patients treated with intravenous cisplatin and patients who underwent surgery. AKI developed 31.2% in the HIPEC group (10 of 32 patients), 11.7% in the surgery group (4 of 34 patients) and 10.5% in intravenous cisplatin group (4 of 38 patients), respectively (p=0.04). Conclusion: HIPEC may not be so safe with regard to kidney function. Every attempt should be taken to decrease kidney damage during this procedure.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.issue5
dc.description.openaccessNO
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume23
dc.identifier.eissn2241-6293
dc.identifier.issn1107-0625
dc.identifier.scopus2-s2.0-85053260437
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9488
dc.identifier.wos443737600042
dc.keywordsAcute kidney injury
dc.keywordsCisplatin
dc.language.isoeng
dc.publisherImprimatur Publications
dc.relation.ispartofJournal Of Buon
dc.subjectOncology
dc.titleHyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorDağel, Tuncay
local.contributor.kuauthorMısırlıoğlu, Selim
local.contributor.kuauthorTanju, Serhan
local.contributor.kuauthorSelçukbiricik, Fatih
local.contributor.kuauthorErus, Suat
local.contributor.kuauthorVatansever, Doğan
local.contributor.kuauthorBalık, Emre
local.contributor.kuauthorTaşkıran, Çağatay
local.contributor.kuauthorDilege, Şükrü
local.contributor.kuauthorMandel, Nil Molinas
local.contributor.kuauthorBuğra, Dursun
local.contributor.kuauthorYaltı, Mehmet Tunç
local.contributor.kuauthorKanbay, Mehmet
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files